Skip to main content
. 2023 Nov 7;42(2):231–247. doi: 10.1007/s40273-023-01322-2

Fig. 3.

Fig. 3

Cost-effectiveness acceptability curve (combined). PSMA prostate-specific membrane antigen, QALY quality-adjusted life-year, WTP willingness to pay